

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Celgene Switzerland LLC</u> <hr/> (Last) (First) (Middle) AON HOUSE 30 WOODBOURNE AVENUE <hr/> (Street) PEMBROKE D0 HM 08 <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 01/26/2017	3. Issuer Name and Ticker or Trading Symbol <u>Jounce Therapeutics, Inc. [JNCE]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) <input type="checkbox"/>	5. If Amendment, Date of Original Filed (Month/Day/Year) <hr/> 6. Individual or Joint/Group Filing (Check Applicable Line) <input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series B-1 Preferred Stock	(1)	(1)	Common Stock	2,831,463	(1)	D ⁽²⁾	

1. Name and Address of Reporting Person* <u>Celgene Switzerland LLC</u> <hr/> (Last) (First) (Middle) AON HOUSE 30 WOODBOURNE AVENUE <hr/> (Street) PEMBROKE D0 HM 08 <hr/> (City) (State) (Zip)

1. Name and Address of Reporting Person* <u>CELGENE CORP /DE/</u> <hr/> (Last) (First) (Middle) 86 MORRIS AVENUE <hr/> (Street) SUMMIT NJ 07901 <hr/> (City) (State) (Zip)
--

Explanation of Responses:

- Each share of Series B-1 Preferred Stock is convertible into 0.271 share of Common Stock without payment of further consideration and will automatically convert into 0.271 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.
- These shares are owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation ("Celgene"), and Celgene has the power to vote, acquire, hold and dispose of all shares. Celgene disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.

Remarks:

/s/ Kevin Mello, Manager,
Celgene Switzerland, LLC 01/26/2017
/s/ Peter N. Kellogg, Executive
Vice President and Chief
Financial Officer, Celgene 01/26/2017
Corporation

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.